Our clinical-academic collaborative partnership is the foundation of our success. From mature technologies already on the market and improving patient care, to a vibrant spinout company portfolio to our emerging technologies, we have an excellent track record of supporting the pathway to clinical adoption.
We showcase a short selection of our exciting technologies here. For a bigger selection of over 40 of our projects, search by clinical or technical area below.
Recent commercial highlights
SurePulse - neonatal heartrate monitoring
The SurePulse optical sensor will enhance resuscitation of babies in neonatal intensive care, and supporting clinical staff to make confident time critical decisions
NuVision - Sight saving wound dressings
Trauma patients rushed to A&E with serious eye injuries can now benefit from NuVision's ground-breaking sight-saving wound dressing
Neonatal transport incubator
We're working to reduce the neonatal vibration exposure to critical care infants during inter-hospital transfer, helping to prevent brain damage
iTraXS Novel endotracheal tube
Our endotracheal tube aims to minimize tracheal injury during intubation and reduce the incidence of ventilator-assisted pneumonia.
Codman antimicrobial brain shunts
Bactiseal(R) antimicrobial catheters, commercialised by Codman (Johnson&Johson) have dramatically cut infection rates for over a million hydrocephalus patients worldwide.
Monica Healthcare - fetal monitoring
Spin-out company, Monica Healthcare, developed a technology for monitoring expectant mothers, which has been used by over 100,000 patients worldwide. Monica was bought by GE Healthcare in 2017.
A to Z of Case Studies
- In the BioBones project, a novel bone graft material; a composite material with similar mechanical properties to bone, but includes a fully resorbable biodegradable glass fibre to allow new bone to grow was developed by a team of materials scientists, biomedical scientists and a consultant maxillofacial surgeon at the Queens Medical Centre in Nottingham.
- Our research is developing targeted therapy, consisting of porous microspheres, which could offer a quick, easy and minimally-invasive treatment that is injected into areas considered to be at high-risk of fracture to promote bone regeneration.